Red Nucleus

Advancing knowledge to improve lives.

🔴🧠

[Red Nucleus @RedNucleusHQ]

Meet your strategic congress objectives with KOL engagement services scalable to your needs, and ensure your data generation planning and key messaging reflect insights from top KOLs, and allied HCPs.

[email protected] | https://t.co/dR4zKTChfv
🔴🧠
#medcomms

[Red Nucleus @RedNucleusHQ]

Meet your strategic congress objectives with KOL engagement services scalable to your needs, and ensure your data generation planning and key messaging reflect insights from top KOLs, and allied HCPs.

[email protected] | https://t.co/dR4zKTChfv
🔴🧠
#medcomms

[Red Nucleus @RedNucleusHQ]

@yourLTEN @Scieducation1 @EisaiUS @kkapp @OmniaGroup @NathanWhitaker Have a great weekend, all!

[Red Nucleus @RedNucleusHQ]

Attending #AUA24? We are! Meet our team in San Antonio—let's discuss how we can enhance your Medical Communications and Learning & Development strategies.

Not at the conference? Reach us via [email protected] or https://t.co/fY8Cv1hmTV.
🔴🧠
#urology #medcomms #MedAffairs

[Red Nucleus @RedNucleusHQ]

Come visit RN MACS at ISPOR in Atlanta! We are presenting a poster on the effects of Accelerated Approval (AA) on Access and Coverage Outcomes.

Questions? Want a copy of the poster? Contact [email protected] or via https://t.co/2w9ZKofO8r.
🔴🧠
#ISPOR2024 #MarketAccess

[Red Nucleus @RedNucleusHQ]

🎈 Congrats to our team at #ISMPPAnnual2024! "Most Visionary Research Award" for our poster abstract USE OF GENERATIVE AI IN MEDICAL COMMUNICATIONS FOR SUMMARIZATION TASKS.

Get your copy of our poster:
[email protected] or https://t.co/2w9ZKofO8r
🧠🔴
#AI #medcomms

[Red Nucleus @RedNucleusHQ]

Meet the Red Nucleus Market Access & Commercialization team at #ASEMBIA2024 in Las Vegas!

Stay ahead of the evolving dynamics in the pricing and reimbursement ecosystem to achieve market success.
🔴Booth 1917
🟣 [email protected]
🔵 https://t.co/EXcAzBbdaW
#AXS24

[Red Nucleus @RedNucleusHQ]

The Red Nucleus team is not only well versed in the rules and regulations in Japan, but we understand the expectations and business culture of the Japanese authorities and how to best engage them.

[email protected] or https://t.co/EXcAzBbdaW .
🔴🧠
#WODC2024 #ASEMBIA2024

[Red Nucleus @RedNucleusHQ]

To encourage the early launch of new drugs in Japan, Chuikyo introduced a “rapid launch premium" to take effect starting this month. Download our PDF for insights on how this will affect your pricing strategies from LinkedIn:

https://t.co/NwPVONZApM
🔴🧠
#WODC2024 #ASEMBIA2024

[Red Nucleus @RedNucleusHQ]

We’re excited to share our innovative approaches using video for hybrid and decentralized trials to collect powerful patient-centered data.

We focus on how to the overcome pitfalls associated with endpoint sensitivity and improve the probability of optimal access for patients.

[Red Nucleus @RedNucleusHQ]

Join us at #WODC2024 in Boston! Are you interested in how to maximize the value and impact of patient centered evidence?

Start leveraging our integrated approaches from trials to access—reach out to us today at [email protected] or via https://t.co/dR4zKTBJpX
🔴🧠

[Red Nucleus @RedNucleusHQ]

Attending #ISMPPAnnual2024? Don't miss our poster, “Use of generative artificial intelligence (AI) in medical communications for summarization tasks”, presented by Danielle Shepherd, PhD.
🔴🧠
Request a copy: https://t.co/ot1HLx7y8U
#genAI #medcomms

[Red Nucleus @RedNucleusHQ]

Questions? Want a copy of the poster? Contact us: https://t.co/RCRcZLExHg

[Red Nucleus @RedNucleusHQ]

Visit the Red Nucleus MACS team at ISPOR in Atlanta! We are presenting a poster on trends in launch prices across US, Canada, EU4 and UK for high-revenue drugs.

10:30 AM – 1:30 PM, May 7, 2024
Poster Session 3, poster code EE276

🔴🧠
#ISPOR2024 #MarketAccess

[Red Nucleus @RedNucleusHQ]

In this poster we will explore:
🔴 Launch list prices and list price differentials between markets for top high-revenue drugs between 2020-23
🟣 Price differentials between markets by therapeutic area, orphan drug status, biologics vs. non-biologics
🔵 Potential rationales

[Red Nucleus @RedNucleusHQ]

Our support services can include:
🟣 Guiding KOL identification;
🟣 Outreach & scheduling;
🟣 Developing discussion guides and talking points;
🟣 Creation of post-meeting summaries;
🟣 Quickly identifying action items and key takeaways;
and more.

[Red Nucleus @RedNucleusHQ]

Meet your strategic congress objectives with KOL engagement services scalable to your needs, and ensure your data generation planning and key messaging reflect insights from top KOLs, and allied HCPs.

[email protected] | https://t.co/dR4zKTChfv
🔴🧠
#medcomms

[Red Nucleus @RedNucleusHQ]

Are you ready for #CMO360? We are! Meet our team in Boston this week—we look forward to discussing the value of video outcome measures in combating pitfalls associated with outcomes sensitivity.

[email protected] | https://t.co/dR4zKTBJpX

🔴🧠
#ClinicalTrials

[Red Nucleus @RedNucleusHQ]

Meet our team at the AMCP Annual Meeting in New Orleans! Let's connect and discuss how our Market Access & Commercialization (MACS) team can help you achieve market success.

We hope to see you there, April 15-18.

[email protected] / https://t.co/2w9ZKofO8r
🔴🧠
#AMCP2024

[Red Nucleus @RedNucleusHQ]

🟣 What is the relationship between US prevalence and launch price, and how do other product attributes affect price?

🔵 What is the impact of being first-in-indication and/or a first-in-class product on US launch price?

#ISPOR2024

[Red Nucleus @RedNucleusHQ]

Come visit the Red Nucleus MACS team at #ISPOR2024 in Atlanta! We are presenting 3 posters leveraging proprietary data from our 2015-22 US non-oncology orphan drug database.
🔴🧠
For your poster copy, contact Dan Krieger [email protected] or via: https://t.co/2w9ZKofO8r

[Red Nucleus @RedNucleusHQ]

We will explore:

🔴 What are the common attributes of orphan drugs and how have these attributes evolved over time?

#ISPOR2024